Skip to main content

Table 2 Clinical characteristics and reported health problem of patients with HIV/AIDS, TASH, Ethiopia, 2019 (n = 511)

From: Health-related quality of life of patients with HIV/AIDS at a tertiary care teaching hospital in Ethiopia

Patient characteristics Number of participant
n (%)
Reported health problem in EQ-5D health dimensions
Mobility
n (%)
Self-care n (%) Usual activity
n (%)
Pain/Discomfort n (%) Anxiety/Depression
n (%)
CD4 (Cells/mm3)
 > 500 138 (27.0) 15 (10.9) 1 (0.7) 11 (8.0) 40 (29.0) 39 (28.3)
350–500 129 (25.2) 22 (17.1) 12 (9.3) 24 (18.6) 65 (50.4) 72(55.8)
200–350 142 (27.8) 21 (14.8) 14 (9.9) 31 (21.8) 84 (59.2) 95 (66.9)
100–200 80 (15.7) 22 (27.5) 10 (12.5) 26 (32.5) 59 (73.7) 60 (75.0)
 < 100 22 (4.3) 5 (22.7) 4 (18.2) 7 (31.8) 14 (63.6) 16 (72.7)
WHO clinical stages (at diagnosis)
I 67 (13.3) 16 (23.9) 3 (4.5) 10 (14.9) 40 (59.7) 42 (62.7)
II 77 (15.2) 11 (14.3) 6 (7.8) 15 (19.5) 40 (51.9) 40 (51.9)
III 190 (37.6) 28 (14.7) 16 (8.4) 32 (16.8) 83 (43.7) 95 (50.0)
IV 171 (33.9) 27 (15.8) 14 (8.2) 40 (23.4) 97 (56.7) 102 (59.6)
Viral load (Copies/mL)
 < 50 copies/ml 440 (86.1) 70 (15.9) 33 (7.5) 81 (18.4) 217 (49.3) 236 (53.6)
51–1000 copies/ml 17 (3.3) 3 (17.6) 2 (11.8) 2 (11.8) 9 (52.9) 10 (58.8)
 > 1000 copies/ml 54 (10.6) 12 (22.2) 6 (11.1) 16 (29.6) 36 (66.7) 36 (66.7)
Treatment regimen
AZT/3TC/EFV 30 (5.9) 5 (16.7) 1 (3.3) 4 (13.3) 10 (33.30 13 (43.3)
AZT/3TC/NVP 28 (5.5) 4 (14.3) 1 (3.6) 3 (10.7) 14 (50) 13 (46.4)
TDF/3TC/EFV 297 (58.1) 49 (16.5) 22 (7.4) 51 (17.2) 146 (49.2) 161 (54.2)
TDF/3TC/NVP 37 (7.2) 4 (10.8) 4 (10.8) 10 (27.0) 19 (51.4) 19 (51.4)
ABC + 3TC + EFV 40 (7.8) 9 (22.5) 5 (12.5) 8 (20.0) 28 (70.0) 27 (67.5)
TDF + 3TC + ATV/r 41 (8.0) 7 (10.8) 3 (7.3) 12 (29.3) 27 (65.9) 29 (70.7)
Others* 38 (7.4) 7 (18.4) 5 (13.2) 11 (28.9) 18 (47.4) 20 (52.6)
Number of medicine
1 208 (40.7) 25 (12) 12 (5.8) 25 (12) 88 (42.3) 93 (44.7)
2 150 (29.4) 26 (17.3) 11 (7.3) 31 (20.7) 84 (56.0) 90 (60.0)
3 91 (17.8) 17 (18.7) 8 (8.8) 21 (23.1) 49 (53.8) 53 (58.2)
4 43 (8.4) 10 (23.3) 3 (7) 12 (27.9) 27 (62.8) 30 (69.8)
 > 4 19 (3.7) 7 (36.8) 7 (36.8) 10 (52.6) 14 (73.7) 16 (84.2)
Duration of treatment
 < 1 year 4 (0.8) 4(100) 1 (25)
1–5 years 120 (23.5) 19 (15.8) 8 (6.7) 27 (22.5) 74 (61.7) 77 (64.2)
 > 5 years 386 (75.7) 66 (17.1) 33 (8.5) 72 (18.7) 183 (47.4) 203 (52.6)
Adherence
Good 466 (91.5) 77 (16.5) 38 (8.2) 90 (19.3) 236 (50.6) 252 (54.1)
Fair 13 (2.6) 3 (13.1) 1 (7.7) 7 (53.8) 9 (69.2)
Poor 30 (5.9) 5 (16.7) 2 (6.7) 9 (30) 17 (56.7) 20 (66.7)
History of Rx failure
Yes 94 (18.4) 17 (18.1) 9 (9.6) 23 (24.5) 60 (63.8) 62 (66)
No 417 (81.6) 68 (16.3) 32 (7.7) 76 (18.2) 202 (48.4) 220 (52.8)
Comorbidities
No 349 (68.3) 47 (13.5) 21 (6) 53 (15.2) 156 (44.7) 175 (50.1)
OIs 41 (8) 5 (12.2) 2 (4.9) 13 (31.7) 25 (61) 28 (68.3)
Non-OIs 121 (23.7) 33 (27.3) 18 (14.9) 33 (27.30 81 (66.9) 79 (65.3)
  1. Rx, treatment; NVP, Nevirapine; ABC, Abacavir; OIs, Opportunistic infections
  2. *Others: ABC + 3TC + NVP, TDF + 3TC + LPV/r and AZT + 3TC + LPV/r